A better option might be to split the business. See if you can sell off the projected future cashflows from sales and plow that cash into drug development. Which leaves the issue of valuing those projected sales, hence Hashan. Just a thought.
A better option might be to split the business. See if you can...
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.29M | |||
| Open | High | Low | Value | Volume |
| 3.2¢ | 3.2¢ | 3.2¢ | $30.50K | 953.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1747120 | 3.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.3¢ | 850000 | 3 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| SNT (ASX) Chart |